IMMUNOTHERAPY

 

 

Immunotherapy, Tuesday 8 December 2020

08:50

Organiser's welcome remarks

Panel discussion
09:00

Keynote Panel: The digital opportunity for pharma– New technology, new investments, new opportunities

Moderator: Howard Califano, Innovation Centre Director, Singapore-MIT Alliance for Research and Technology
Carl Firth, Chief Executive Officer, ASLAN Pharmaceuticals
Nilesh Wadhwa, Director, New Ventures And Transactions, Johnson & Johnson Innovation, Asia Pacific, Johnson & Johnson
Dr Stephen Christopher, Regional Medical Lead, APAC, WHC and EP, Bayer
Kulbir Sandhu, APAC Regional Head, VP of Digital Strategy, Roche Pharma
Panel discussion
10:00

Keynote Panel: Creating a collaborative drug development ecosystem

Moderator: Sharon Chan, Head JLABS at Shanghai, Johnson & Johnson
Vishal Doshi, Chief Executive Officer, AUM Biosciences
Raymond Stevens, CEO and Co-founder, ShouTi Pharma
Andy Li, CEO, BioSense
Kevin Chen, CEO, Elixiron
Naheed Kurji, Co-founder, President and CEO, Cyclica Inc.
Harish Dave
Immunotherapy
11:00

Drug development – critical need to move beyond single agent therapy

Harish Dave, Chief Medical Officer, AUM Biosciences
Mark Diamond
Immunotherapy
11:30

ATL1102 for Duchenne muscular dystrophy (DMD)

Mark Diamond, Managing Director and CEO, Antisense Therapeutics Ltd
Fredy Chu
Immunotherapy
12:00

Gene and Cell Therapy Outsourcing Success Factors

Fredy Chu, Vice President, GenScript ProBio
Panel discussion
Immunotherapy
12:30

Panel: Partnering for the next immuno-oncology breakthrough

Moderator: Prof Cristina Stefan, Consultant, Institute of Oncology, Adjunct Associate Professor, SingHealth Duke-NUS Global Health Institute (SDGHI)
Dr Ogan Gurel, Chief Strategy Officer, CTCELLS and Chief Marketing Officer, Eidware/SoundMind and Invited Professor, DGIST
Diana Bonilla, Technical Application Specialist (US), Cytek Biosciences, Inc.
Ying Pan, Senior Director, Translational Medicine and Biomarker, CStone
WeiWei Zhao, Senior Director, Asia Operations, Pharma Services, Neogenomics
Dr Tina Wang
Immunotherapy
13:30

HBV-specific TCR-T Cell Therapy in Hepatocellular Carcinoma

Dr Tina Wang, Chief Operating Officer, Lion TCR
Jerome Boyd-Kirkup
Immunotherapy
14:00

Driving immuno-oncology with rational antibody discovery

Jerome Boyd-Kirkup, Chief Scientific Officer, Hummingbird Bioscience
Ignacio Asial
Immunotherapy
14:30

Multifunctional antibodies and immunotherapy

Ignacio Asial, Founder And Chief Executive Officer, DotBio
Qingfeng Chen
Immunotherapy
15:00

Humanized mouse model: A tool to address human specific questions in biomedical research

Qingfeng Chen, Principal Investigator, Institute of Molecular and Cell Biology (IMCB) Singapore, A*STAR
Chee Mun Kuan
Immunotherapy
15:30

Organ-on-a-chip models for research, drug development and diagnostics

Chee Mun Kuan, Executive Director and Co-Founder, AIM Biotech Pte Ltd
Kaushik Deb
Immunotherapy
16:00

Development of cGMP Manufacturing Platforms for Cellular Immunotherapies: MSCs, NK cells and T cells

Kaushik Deb, CEO, DiponEd BioIntelligence
Sebastian Stolzenberg
Immunotherapy
16:30

Molecular insights into key mechanistic steps of an adaptive immune response

Sebastian Stolzenberg, Postdoctoral Project Leader, Freie University of Berlin
Adrian Teo
Immunotherapy
17:00

Clinical grade Asian human induced pluripotent stem cell-derived beta cells for diabetes therapy: Innovative Cell Therapy Platform for Asian Diabetes

Adrian Teo, Co-Founder, BetaLife Pte Ltd
last published: 09/Dec/20 03:45
BOOK NOW

 

 

 

 

DOWNLOAD PROSPECTUS

 

 

For speaking, sponsorship and exhibition opportunities contact jonathan.mottram@terrapinn.com
Tel: +65 6322 2738